C-40 | Procedural Outcomes of Acute Pulmonary Embolism Among Active Cancer Patients: A Nationwide Cohort Analysis

Abstract

Pulmonary embolism (PE) is one of the most serious complications in cancer patients. There are different treatment modalities for PE patients with very limited data available on the outcomes among cancer Patients. This analysis included data from the National Inpatient Sample between January 2016 and December 2020. We reported the baseline characteristics and hospital outcomes of hospitalized cancer patients with PE among the different treatment modalities. We identified 362,749 hospitalized cancer patients with acute PE during 2016-2020. Median age for was systemic thrombolysis (ST) 70.3%, mechanical thrombectomy (MT) 20.5% Catheter Directed Thrombolysis (CDT) 6.46% and surgical Embolectomy (SE) 2.7% was (66 vs 68 vs 66 vs 60, p <.0001). Overall, SE was associated with higher the Inpatient mortality (24% vs 14.17% vs 6.67% vs 20.37%, p <.0001), GI bleeding (8% vs 3.66% vs 2.50% vs 3.44%, p <.0001 ), major bleeding (16% vs 14.92% vs 6.67% vs 14.61%,p <.0001) and utilization of ECMO (14% vs 1.05% vs 0% vs 0.31%, p <.0001) compared to (MT,CDT,ST). However ST had the highest risk of intracranial hemorrhage (2.45% vs 0.83% vs 1.83% vs 0%, p<.0001) compared to (CDT,MT,SE). Patients undergoing SE had the longest length of median stay (13 days vs 6 days) and the highest inflation-adjusted mean cost ($69,653.93 vs $33,077.67) compared to other groups. ST is the most commonly utilized treatment mortality among cancer patients with PE and has the highest risk of intracranial hemorrhage. SE is the least used modality but it has the highest mortality rate and highest risk of GI and major bleeding.